Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia switches chloramphenicol eye drops

This article was originally published in The Tan Sheet

Executive Summary

Australia moves chloramphenicol-containing eye drops to nonprescription distribution by pharmacists, harmonizing the country's regulation with New Zealand's. The National Drugs and Poisons Schedule Committee in October said that other nonprescription products are indicated for mild cases of bacterial conjunctivitis, but it is "sensible to allow pharmacists to supply cholramphenicol for the treatment of more severe, uncomplicated cases." Australia and New Zealand are harmonizing requirements for therapeutic products and establishing a joint regulatory scheme under the Trans-Tasman Mutual Recognition Arrangement (1"The Tan Sheet" Feb. 2, 2009). Chloramphenicol-containing eye drops remain Rx in the U.S

You may also be interested in...



Therapeutic Product Regulatory Reforms Considered Down Under

Australia's Therapeutic Goods Association plans to implement a number of regulations to update and streamline the existing framework for over-the-counter and prescription drugs as well as medical devices

Kite Strikes CAR-T Access & Discount Deal For Tecartus In England

Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.

Germany First As Pfenex And Alvogen Biosimilar Forsteo Is Launched

After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel